205 related articles for article (PubMed ID: 28607011)
1. Retrospective Cohort Analysis of Liposomal Amphotericin B Nephrotoxicity in Patients with Hematological Malignancies.
Stanzani M; Vianelli N; Cavo M; Maritati A; Morotti M; Lewis RE
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28607011
[TBL] [Abstract][Full Text] [Related]
2. Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real-life study.
Falci DR; da Rosa FB; Pasqualotto AC
Mycoses; 2015 Feb; 58(2):104-12. PubMed ID: 25590436
[TBL] [Abstract][Full Text] [Related]
3. Occurrence and improvement of renal dysfunction and serum potassium abnormality during administration of liposomal amphotericin B in patients with hematological disorders: A retrospective analysis.
Yamazaki H; Kondo T; Aoki K; Yamashita K; Takaori-Kondo A
Diagn Microbiol Infect Dis; 2018 Feb; 90(2):123-131. PubMed ID: 29203252
[TBL] [Abstract][Full Text] [Related]
4. Impact of liposomal amphotericin B on renal function in critically ill patients with renal function impairment.
Alvarez-Lerma F; Soriano MC; Rodríguez M; Catalán M; Llorente AM; Vidart N; Garitacelaya M; Maraví E; Fernández E; Alvarado F; López M; Alvarez-Sánchez B; Espinosa J; Quintana E;
Rev Esp Quimioter; 2012 Sep; 25(3):206-15. PubMed ID: 22987267
[TBL] [Abstract][Full Text] [Related]
5. The evaluation of frequency of nephrotoxicity caused by liposomal amphotericin B.
Kato H; Hagihara M; Yamagishi Y; Shibata Y; Kato Y; Furui T; Watanabe H; Asai N; Koizumi Y; Mikamo H
J Infect Chemother; 2018 Sep; 24(9):725-728. PubMed ID: 29773439
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of renal effects of liposomal amphotericin B in children with malignancies with KDIGO and RIFLE criteria.
Devrim F; Çağlar İ; Acar SO; Akkuş Ş; Dinçel N; Yılmaz E; Tahta N; Demirağ B; Karapınar TH; Gözmen S; Oymak Y; Vergin C; Bayram N; Devrim İ
Nephrol Ther; 2021 Dec; 17(7):507-511. PubMed ID: 34535406
[TBL] [Abstract][Full Text] [Related]
7. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study.
Chamilos G; Luna M; Lewis RE; Chemaly R; Raad II; Kontoyiannis DP
Clin Ther; 2007 Sep; 29(9):1980-6. PubMed ID: 18035197
[TBL] [Abstract][Full Text] [Related]
8. [Impact on renal function of an early switch from conventional to liposomal amphotericin B formulation in the empirical treatment of fungal infections].
Isnard F; Tilleul P; Laporte JP; Chevallier P; Pigneux A; Lafuma A; Monchecourt F; Mahi L; Deray G
Med Mal Infect; 2008 Apr; 38(4):208-14. PubMed ID: 18191521
[TBL] [Abstract][Full Text] [Related]
9. The clinical usage of liposomal amphotericin B in patients receiving renal replacement therapy in Japan: a nationwide observational study.
Obata Y; Takazono T; Tashiro M; Ota Y; Wakamura T; Takahashi A; Sato K; Miyazaki T; Nishino T; Izumikawa K
Clin Exp Nephrol; 2021 Mar; 25(3):279-287. PubMed ID: 33179180
[TBL] [Abstract][Full Text] [Related]
10. Factor analysis of acute kidney injury in patients administered liposomal amphotericin B in a real-world clinical setting in Japan.
Takazono T; Tashiro M; Ota Y; Obata Y; Wakamura T; Miyazaki T; Nishino T; Izumikawa K
Sci Rep; 2020 Sep; 10(1):15033. PubMed ID: 32929112
[TBL] [Abstract][Full Text] [Related]
11. Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex.
Wade RL; Chaudhari P; Natoli JL; Taylor RJ; Nathanson BH; Horn DL
Diagn Microbiol Infect Dis; 2013 Jul; 76(3):361-7. PubMed ID: 23774005
[TBL] [Abstract][Full Text] [Related]
12. Coadministration of Liposomal Amphotericin B and Contrast Medium Does Not Increase Risk of Kidney Injury.
O'Horo JC; Osmon DR; Abu Saleh OM; Marcelin JR; Gharaibeh KA; Hamadah AM; Barwise AK; Kayhart BM; McDonald JS; McDonald RJ; Leung N
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533242
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Low-Dose Liposomal Amphotericin B in Adult Patients Undergoing Unrelated Cord Blood Transplantation.
Yasu T; Konuma T; Oiwa-Monna M; Kato S; Tanoue S; Isobe M; Mizusawa M; Kuroda S; Takahashi S; Tojo A
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104271
[TBL] [Abstract][Full Text] [Related]
14. Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia.
Annino L; Chierichini A; Anaclerico B; Finolezzi E; Norata M; Cortese S; Cassetta MI; Fallani S; Novelli A; Girmenia C
Antimicrob Agents Chemother; 2013 Jun; 57(6):2596-602. PubMed ID: 23529741
[TBL] [Abstract][Full Text] [Related]
15. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial.
Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J
Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069
[TBL] [Abstract][Full Text] [Related]
16. COMPARATIVE EFFECTIVENESS AND SAFETY BETWEEN AMPHOTERICIN B LIPID-FORMULATIONS: A SYSTEMATIC REVIEW.
Grazziotin LR; Moreira LB; Ferreira MAP
Int J Technol Assess Health Care; 2018 Jan; 34(3):343-351. PubMed ID: 29897025
[TBL] [Abstract][Full Text] [Related]
17. Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients.
Peleg AY; Woods ML
J Antimicrob Chemother; 2004 Oct; 54(4):803-8. PubMed ID: 15308606
[TBL] [Abstract][Full Text] [Related]
18. Continuously infused amphotericin B deoxycholate for primary treatment of invasive fungal disease in acute myeloid leukaemia.
Rothenbühler C; Held U; Manz MG; Schanz U; Gerber B
Hematol Oncol; 2018 Apr; 36(2):471-480. PubMed ID: 29431860
[TBL] [Abstract][Full Text] [Related]
19. Potential Usefulness of Early Potassium Supplementation for Preventing Severe Hypokalemia Induced by Liposomal Amphotericin B in Hematologic Patients: A Retrospective Study.
Okada N; Azuma M; Imanishi M; Zamami Y; Kirino Y; Nakamura T; Teraoka K; Abe M; Ishizawa K
Clin Ther; 2018 Feb; 40(2):252-260. PubMed ID: 29305017
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of hepatotoxicity and nephrotoxicity of liposomal amphotericin B (L-AMB).
Patel GP; Crank CW; Leikin JB
J Med Toxicol; 2011 Mar; 7(1):12-5. PubMed ID: 21057910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
